Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
An erratum to this article was published (Circulation, 21 Mar 2017 ↗)
Authors' conclusion
Among patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a reduced risk of all-cause mortality or recurrent hospitalization for adverse events compared with standard-of-care VKA plus DAPT.
Study context
- Population
- Stented patients with nonvalvular AF
- Participants
- 2,124 patients
- Comparison
- Rivaroxaban-based regimens vs dose-adjusted vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT)
- Primary endpoint
- All-cause mortality or recurrent hospitalization for an adverse event
Methodological details1:1:1 randomisation, Hospitalization cause classified blinded to treatment assignment
- 1:1:1 randomisation
- Hospitalization cause classified blinded to treatment assignment
Primary result
As reported in the abstract
Each group vs group 3Hazard ratio (95% CI)P value
Group 1NNT=15
0.79(0.66–0.94)
P = 0.008Group 2NNT=10
0.75(0.62–0.90)
P = 0.002Further findings
All-cause death plus rehospitalization potentially from a CV cause
All-cause death plus hospitalization potentially from bleeding
- All-cause death plus rehospitalization potentially from a CV cause: Group 1 vs Group 3 P=0.001
- All-cause death plus rehospitalization potentially from a CV cause: Group 2 vs Group 3 P=0.011
- All-cause death plus hospitalization potentially from bleeding: Group 1 vs Group 3 P=0.032
- All-cause death plus hospitalization potentially from bleeding: Group 2 vs Group 3 P=0.012
Other forms of rehospitalization
- Not reduced in the rivaroxaban arms vs the VKA arm
Original publication
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. Published 14 November 2016. doi:10.
Summarised from the published abstract; every number is checked against it